Anthrocell
Anthrocell is an Australian biotechnology company focused on developing a new generation biopharmaceutical production platform, the ACX™ system, which produces fully human recombinant proteins for better health outcomes. The company aims to improve clinical effectiveness, reduce time to market, and lower production costs of human therapeutic drugs, leveraging its proprietary technology derived from human immune system cells.
Industries
Nr. of Employees
small (1-50)
Anthrocell
Products
Bio-better monoclonal antibody candidates (preclinical oncology)
A pipeline of monoclonal antibody candidates developed using a human-cell expression platform to improve post-translational modification profiles and intended clinical performance; candidates are in in-vitro and in-vivo preclinical stages for breast and colorectal cancer indications.
Anthrocell Expression System
A proprietary fully human cell-based expression system (ACX) designed for high yield production of fully human monoclonal antibodies and biopharmaceutical proteins with human post-translational modifications.
Anthrocell Expression System: ACX™
A 4th generation 100% human expression platform derived from mature human lymphocyte cells, optimized for the production of biopharmaceutical protein drugs and monoclonal antibodies with fully human glycosylation patterns.
Anthrocell Bioservices
Anthrocell Bioservices (ABS) supports users of the ACX platform with expertise in cell line and bioprocess development, as well assistance in design of pre-clinical efficacy and toxicology studies, along with small-scale production of materials for pre-clinical development.
AC-02
An improved bio-better version of a different breast cancer drug currently at an earlier development stage, about to commence in-vitro pre-clinical development.
AC-01
An improved bio-better version of a leading breast cancer drug exhibiting target chemical properties and undergoing in-vivo pre-clinical development.
Bio-better monoclonal antibody candidates (preclinical oncology)
A pipeline of monoclonal antibody candidates developed using a human-cell expression platform to improve post-translational modification profiles and intended clinical performance; candidates are in in-vitro and in-vivo preclinical stages for breast and colorectal cancer indications.
Anthrocell Expression System
A proprietary fully human cell-based expression system (ACX) designed for high yield production of fully human monoclonal antibodies and biopharmaceutical proteins with human post-translational modifications.
Anthrocell Expression System: ACX™
A 4th generation 100% human expression platform derived from mature human lymphocyte cells, optimized for the production of biopharmaceutical protein drugs and monoclonal antibodies with fully human glycosylation patterns.
Anthrocell Bioservices
Anthrocell Bioservices (ABS) supports users of the ACX platform with expertise in cell line and bioprocess development, as well assistance in design of pre-clinical efficacy and toxicology studies, along with small-scale production of materials for pre-clinical development.
AC-02
An improved bio-better version of a different breast cancer drug currently at an earlier development stage, about to commence in-vitro pre-clinical development.
AC-01
An improved bio-better version of a leading breast cancer drug exhibiting target chemical properties and undergoing in-vivo pre-clinical development.
Services
Contracted development and optimisation of production cell lines compatible with a human-cell expression platform.
Provision of small-batch production of biologic materials for preclinical in-vitro and in-vivo studies.
Assistance in designing preclinical efficacy and toxicology studies to support biologic development.
Licensing agreements to grant research and commercial access to a human-cell expression platform.
Collaborative R&D engagements with external partners to develop monoclonal antibodies and bio-better biologics.
Contracted development and optimisation of production cell lines compatible with a human-cell expression platform.
Provision of small-batch production of biologic materials for preclinical in-vitro and in-vivo studies.
Assistance in designing preclinical efficacy and toxicology studies to support biologic development.
Licensing agreements to grant research and commercial access to a human-cell expression platform.
Collaborative R&D engagements with external partners to develop monoclonal antibodies and bio-better biologics.
Expertise Areas
- Human cell-based expression systems
- Monoclonal antibody discovery and preclinical development
- Cell-line development and optimization
- Bioprocess development and scale-up
Key Technologies
- Human lymphocyte-derived expression systems
- Mammalian suspension cell culture
- High-efficiency transfection and stable clone generation
- Glycosylation and PTM analysis
News & Updates
Announcement of upcoming meetings and events.
Announcement of new shop opening.
An article explaining the basics of social media marketing.
An article providing tips on handling SEO effectively.
A list of the top apps in 2017.
Tips for effective web design.
Announcement of upcoming meetings and events.
Announcement of new shop opening.
An article explaining the basics of social media marketing.
An article providing tips on handling SEO effectively.
A list of the top apps in 2017.
Tips for effective web design.